-
Search
 
 
  
 Other POC-IT Resources
 

POC-IT Center
ABX Guide
HIV Guide

 Related Sites
 

PAHO
Medical Association of Trinidad
CHRC guidelines
Trinidad and Tobago Ministry of Health
CDAP - The Chronic Disease Assistance Programme

 Guide Editors
 Editor In Chief
    Christopher D. Saudek, M.D.

Managing Editor
    Rita Rastogi Kalyani, M.D., M.H.S.

Advisor
    Frederick L. Brancati, M.D., M.H.S.
 

Management> Type 2 Diabetes>
Diabetes Guide Home PageEmail this module to a friend

Type 2 Diabetes: Environmental Risk Factors and Screening

Ari S. Eckman, M.D. and Rita Rastogi Kalyani, M.D.
02-04-2011

DEFINITION

  • Includes risk factors other than genetic determinants (usually associated with positive family history) for type 2 diabetes (T2DM). See module on "Genetic risk factors for type 2 diabetes" for summary of genetic determinants. 
  • Often used to screen for T2DM.

EPIDEMIOLOGY

  • American Diabetes Association (ADA) recommends diabetes screening for: 1) asymptomatic persons <45 years old of age who are overweight (BMI>25 kg/m2) with any one of the high-risk factors (see below) for type 2 diabetes; or 2) persons >45 years of age (particularly with BMI>25 kg/m2) every three years or more regularly depending on risk status. (ADA Standards of Medical Care).
  • In retrospective study of over 46,000 patients > 20 years without diabetes seen at a large academic physician practice, 66% met ADA criteria for diabetes screening; of these, 11% were <45 years with risk factors (Sheehy).
  • 86% of those eligible for screening had 1 or more glucose tests performed; 5% of those tested were diagnosed with diabetes.
  • Prevalence of high-risk factors: age >45 years (55%); overweight (52%); hypercholesterolemia (50%); hypertension (26%); vascular disease (6%); high-risk ethnic group (4%); prediabetes (0.4%); polycystic ovarian disease (0.4%)
  • High-risk factors associated with greatest yield of new diabetes diagnoses: prediabetes (16%); polycystic ovarian disease (13%); and vascular disease (10%)
  • The U.S. Preventive Services Task Force (USPSTF) has recommended diabetes screening for patients with hypertension and hyperlipidemia since 2000; however, in the most recent 2008 update, screening only advised for asymptomatic adults with sustained blood pressure >135/80 mm Hg (USPSTF guidelines).
  • Only 26% met USPSTF 2008 criteria for diabetes screening (Sheehy)

DIAGNOSIS

  • ADA high-risk factors: physical inactivity (exercising < 3 times a week); high-risk ethnicity (e.g. African-American, Latin American, Native American, Asian American, or Pacific Islander); women who delivered a baby >9 lbs (4kg) or had diagnosed gestational DM; hypertension; high-density lipoprotein cholesterol (HDL-C) < 35mg/dL (0.90 mmol/L) and/or triglycerides >250 mg/dL (2.82 mmol/L); women with polycystic ovarian syndrome; previously identified impaired fasting glucose or impaired glucose tolerance; clinical conditions associated with insulin resistance (e.g. severe obesity and acanthosis nigricans); history of cardiovascular disease. First degree relative with T2DM (i.e. genetic risk factor) is also a criterion. (ADA Standards of Medical Care).
  • Abdominal obesity: waist circumference > 40 inches (102 cm) in males, >36 inches (88 cm) in females, or increased waist -to-hip circumference ratio that is >0.95 in Caucasian men and >0.85 in Caucasian women confers higher risk; cut-offs may vary by ethnicity (Chan).
  • Other risk factors: older age (Cowie); parity (Nicholson); low (versus moderate) alcohol use (Koppes); cigarette smoking (Willi); also (transiently) stopping smoking (Yeh); stress (Golden); low socioeconomic status particularly among Latin Americans and African Americans (Aviel-Curiel; Schootman); diet (i.e. high-fat, low -fiber, Western diet) (Shai); low magnesium intake (Larsson); soda consumption (Nettleton).
  • Chronic environmental exposures: inorganic arsenic in drinking water (Navas-Acien); organophosphate and chlorinated pesticides (Montgomery); bisphenol A (a monomer used to make hard, polycarbonate plastics) and some epoxy resins (Lang).
  • Urbanization trends: In Pacific island of Nauru, Pima Indians took on a more Western lifestyle leading to more obesity, and diabetes incidence went from nearly 0 to about 50% (Zimmet). In India, Asian Indians living in rural communities had diabetes prevalence of 2%, increasing to 10% after moving to an urban environment (Ramachandran).

CLINICAL TREATMENT

Modifiable risk factor management for prevention of diabetes

  • Weight loss (~5 - 10%) (Knowler)
  • Increase physical activity (>30 minutes at least 3 - 5 days/week) (Knowler)
  • Decrease triglycerides and increase HDL with lifestyle modification or medication if needed (see Dyslipidemia module)
  • Treat hypertension with lifestyle modification or medication if needed
  • Cardiovascular disease prevention
  • Eliminate soft drinks and sugary foods from diet
  • High-fiber diet
  • Smoking cessation, though may transiently increase risk of T2DM (Yeh)
  • Stress management

EXPERT COMMENTS

  • Modifiable risk factors including obesity and physical inactivity are the strongest environmental risk factors for developing T2DM.
  • T2DM can be effectively prevented by lifestyle changes in high-risk persons (~60% risk reduction) as demonstrated in the Diabetes Prevention Program.
  • Individuals from high-risk ethnic groups who also have other diabetes risk factors may be particularly vulnerable. 
  • Diabetes screening programs can identify individuals with high-risk factors.
  • Early risk factor identification and modification is essential for prevention of diabetes.

Basis for Recommendations

  • American Diabetes Association; Standards of medical care in diabetes--2010.; Diabetes Care; 2010; Vol. 33 Suppl 1; pp. S11-61;
    ISSN: 1935-5548;
    PUBMED: 20042772
    Rating: Basis for recommendation
    Comments:American Diabetes Association consensus statement describing risk factors for diabetes and criteria for screening in asymptomatic individuals.

REFERENCES


 
 
Home
 
Overview
 
Management
 
Complications and Comorbidities
 
Medications
 
Clinical Tests
 
Trinidad and Tobago Specific Modules
 
View All Modules